Restaging after induction therapy for non-small cell lung cancerRestaging after induction therapy for non-small cell lung cancer
Faculty of Medicine and Health Sciences
Antwerp Surgical Training, Anatomy and Research Centre (ASTARC)
NATO science series. Series I, Life and behavioural sciences
NATO Advanced Research Workshop on New Advances in Thoracic Oncology, APR 28-30, 2002, Olginka, RUSSIA
350(2005), p. 27-35
University of Antwerp
Patients with persisting involvement of mediastinal lymph nodes after neo-adjuvant therapy have a poor prognosis and do not benefit from surgical resection. Precise restaging after induction treatment is important to determine further treatment and prognosis. Computed tomography and magnetic resonance imaging have a low accuracy in predicting response after induction therapy. Positron emission tomo-graphy has a high sensitivity to detect residual viable disease in the primary turnout but not in the mediastinal. lymph nodes. Invasive staging remains necessary to precisely assess mediastinal response. Remediastinoscopy, although technically difficult, has an accuracy of 80 % and provides histological proof of mediastinal downstaging. In this way, it is a useful procedure to select patients for thoracotomy after induction therapy. The ultimate overall pathologic response can only be determined by thoracotomy with excision of the primary tumour, hilar and mediastinal lymph nodes.